Replies to post #163934 on Biotech Values

[oc631]

The trial makes sense for the Russian market specifically

So a GT1 patient in Russia is different than a GT1 patient in the U.S. There's proof that the Sofo/Riba combo isn't potent enough in this genotype. GILD is on record stating this.



What's wrong with Sofo/interferon-based therapy? There's a combo that works.